Pulmonology

Eosinophilic Disorders

Questions discussed in this category

Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?

Does the severity of asthma play a role in decision making?

2 Answers available

Do you utilize cytokine panels to guide treatment of patients with EGPA?

2 Answers available

What is your second line therapy for patients with EGPA with mainly pulmonary and sinonasal features who did not respond to mepolizumab 300 mg/month and still require high doses of steroid?

2 Answers available

Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?

1 Answer available

What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?

1 Answer available

Which EGPA patients are most likely to benefit from treatment with anti-IL-5 agents such as mepolizumab?

1 Answer available

Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?

2 Answers available

Papers discussed in this category

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Medicine (Baltimore),

The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

The New England journal of medicine, 2017-05-18

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Arthritis & rheumatology (Hoboken, N.J.), 2021 Dec 30

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.

European journal of clinical investigation, 2024 Oct 10

Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta-analysis of eight studies.

Clinical and experimental rheumatology, 2019

Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma.

PloS one, 2015 Mar 26

Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

Frontiers in immunology, 2022 Jun 10

Serum Proteomic Analysis Identifies SAA1, FGA, SAP, and CETP as New Biomarkers for Eosinophilic Granulomatosis With Polyangiitis.

Rheumatology (Oxford, England), 2025 Mar 01

SERPINA3, FGA, AGP1, ITIH3 and SAA1 as novel biomarkers for eosinophilic granulomatosis with polyangiitis diagnosis and activity assessment.

The Journal of allergy and clinical immunology, 2022 Jun 27

Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.

Related Topics in Pulmonology